Drug Type Monoclonal antibody |
Synonyms OCT 50, OCT50 |
Target |
Mechanism CD22 modulators(CD22 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Octagon Therapeutics, Inc.Startup |
Active Organization Octagon Therapeutics, Inc.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Lupus Erythematosus, Cutaneous | Preclinical | US | Octagon Therapeutics, Inc.Startup | 11 Jun 2024 |
Multiple Sclerosis | Preclinical | US | Octagon Therapeutics, Inc.Startup | 11 Jun 2024 |
Sjogren's Syndrome | Preclinical | US | Octagon Therapeutics, Inc.Startup | 11 Jun 2024 |
Systemic Lupus Erythematosus | Preclinical | US | Octagon Therapeutics, Inc.Startup | 11 Jun 2024 |